Audit begins with product truth
In pharmaceutical manufacturing, the financial statements depend on a deeper record: whether materials were controlled, processes performed as approved, deviations investigated, data preserved and product released on sound evidence. The Audit Committee Chair must treat quality and data integrity as foundational to revenue, inventory, provisions, liability and licence to operate—not as a specialist presentation delivered after the accounts.
Assurance architecture
The Chair will align internal audit, quality assurance, statutory audit, compliance and enterprise risk so that gaps do not fall between their scopes. High-risk themes include batch and laboratory data, access and audit trails, deviations, out-of-specification results, change control, vendor qualification, stability, complaints, recalls, pharmacovigilance interfaces, computer-system validation and corrective-action effectiveness.
Management should report the age, recurrence and product/site consequence of observations. Closure requires proof that root cause and control behaviour changed; a revised procedure or training record alone is weak evidence. The committee must be able to see where quality pressure, capacity or delivery incentives influence escalation.
Financial judgements beneath the operation
Inventory valuation and shelf life, rejected or quarantined stock, yield, scrap, product returns, customer claims, regulatory remediation, litigation, impairment and capitalised development require operating evidence. Revenue should be reconciled to release, shipment, acceptance and rights of return. Capital investment needs post-completion review against validated capacity, yield, compliance and actual cash benefit.
The Chair will also scrutinise related parties, distributor or customer credit, foreign exchange, tax positions and material third parties. Private sessions with external and internal auditors, the quality leader and the compliance officer should be routine when warranted—not a sign of crisis.
NRC contribution
As an NRC member, the director will assess succession and capability for the CEO and leaders of quality, manufacturing, regulatory, finance and R&D. The committee should understand key-person dependence at sites and in specialist disciplines. Incentives must not encourage output, filing or delivery at the expense of right-first-time quality and transparent escalation.
First two committee cycles
The incoming Chair will review one product family from supplier qualification through batch record, laboratory result, release, sale and complaint, then compare that evidence with the financial treatment. A second review will examine overdue high-risk findings and test whether closure was independently verified. These exercises will establish the new assurance agenda.
Qualifications
Relevant candidates include pharma CFOs, quality or manufacturing leaders with enterprise governance depth, audit partners, regulators and CEOs of highly regulated manufacturing businesses. They must understand both GMP consequence and listed-company financial oversight. Previous Audit Committee leadership is strongly preferred. Appointment requires independence, conflicts clearance and databank compliance. Site visits and additional availability during a regulatory, quality or recall event are inherent in the mandate.
Registration on the IICA Independent Directors Databank is required before appointment. A DIN is not needed to apply: where an appointee does not yet hold one, it is obtained through the appointing company at the point of appointment.